

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 May 2003 (22.05.2003)

PCT

(10) International Publication Number
WO 03/042212 A1(51) International Patent Classification⁷: C07D 471/04

(21) International Application Number: PCT/HU02/00120

(22) International Filing Date:
13 November 2002 (13.11.2002)

(25) Filing Language: Hungarian

(26) Publication Language: English

(30) Priority Data:
P0104873 13 November 2001 (13.11.2001) HU(71) Applicant (for all designated States except US): EGIS
GYÓGYSZERGYÁR RT. [HU/HU]; Keresztúri út 30-38,
H-1106 Budapest (HU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PONGÓ, László


[HU/HU]; Hold u. 31, H-2144 Kerepes (HU). REITER, József [HU/HU]; Tövis u. 32/b, H-1022 Budapest (HU). SIMIG, Gyula [HU/HU]; Hollósy S. u. 25, H-1126 Budapest (HU). BERECS, Gábor [HU/HU]; Bihari út 17, H-1107 Budapest (HU). CLEMENTIS, György [HU/HU]; Regős u. 9, H-1118 Budapest (HU). SLÉGEL, Péter [HU/HU]; Eötvös u. 31, H-1067 Budapest (HU). SZULÁGYI, János [HU/HU]; Reviczky ezredes u. 8, H-1033 Budapest (HU). KONCZ, László [HU/HU]; Szőlő u. 1/a, H-2146 Mogyoród (HU). VERECZKEYNÉ DONÁTH, Györgyi [HU/HU]; Lajos u. 49/b, H-1036 Budapest (HU). NAGY, Kálmán [HU/HU]; Turista u. 2/a, H-1025 Budapest (HU). KÖRTVÉLYESSY, Gyuláné [HU/HU]; Bimbó út 30, H-1022 Budapest (HU).

(74) Agent: ADVOPATENT; Office of Patent and Trademark Attorneys, P.O. Box 11, H-1251 Budapest (HU).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

[Continued on next page]


(54) Title: IMPROVED PROCESS FOR THE PREPARATION OF 3-{2-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL]ETHYL}-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE




(I)



(II)



(XIV)



(V)

(57) Abstract: The invention relates to a process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula (I), and pharmaceutically acceptable acid addition salts thereof by subjecting the oxime of the Formula (II), to ring-closure in the presence of an alkali hydroxide, alkali carbonate or alkali-C₁₋₄ alkoxide in an inert organic solvent, converting the base of the Formula I thus obtained into an acid addition salt or setting free the base of the Formula I from an acid addition salt thereof which comprises reacting a halogen derivative of the general Formula (XIV), (wherein Hal is halogen) with piperidine oxime derivative of the Formula (V), or an acid addition salt thereof in the presence of a base, and using by the ring-closure of the oxime of the Formula II formed a C₁₋₄-alkanol as inert solvent. The process of the present invention enables the economical preparation of a product having a purity suitable for pharmaceutical purposes.

WO 03/042212 A1

BEST AVAILABLE COPY



GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

IMPROVED PROCESS FOR THE PREPARATION OF 3-{2-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL]ETHYL}-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE

TECHNICAL FIELD OF THE INVENTION

The invention relates to the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.


The compound 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula



is a well-known antipsychotic agent having the INN (International Non-Proprietary Name) risperidone which can be used for the treatment of diseases related to serotonin release.


TECHNICAL BACKGROUND OF THE INVENTION

Several processes for the preparation of risperidone of the Formula I are disclosed in HU-P 195,793 and the corresponding EP-P 196,132. According to one of said processes a reactive derivative of the general Formula



III


(wherein W is a reactive group e.g. halogen or an O-sulfonic acid ester group) is reacted in an inert solvent with a benzisoxazol derivative of the Formula




IV

The disadvantage of said process is that the benzisoxazol derivative of the Formula IV is prepared by boiling the corresponding piperidine oxime derivative of the Formula

3




in a strongly alkaline medium and in the course of this reaction not only the desired fluorine atom in the ortho-position reacts but - according to our experiments – the fluorine atom in the para-position takes also part in the reaction at a rate of about 5 %, to yield the dimer of the Formula



As shown in comparative Example 1 said dimer of the Formula VI contaminates the desired benzisoxazol derivative of the Formula IV. The dimer of the Formula VI is significantly less soluble than the benzisoxazol of the Formula IV and therefore practically it cannot be removed by recrystallization. Consequently, on converting the benzisoxazol derivative of the Formula IV contaminated with the dimer of the Formula VI to


risperidone, said end-product contains about 3 % of the impurity dimer of the Formula



VII

Since the dimer of the Formula VII is much less soluble than risperidone, it is practically impossible to remove the dimer of the Formula VII from risperidone. This is clearly shown in comparative Example 2.


According to another known process risperidone is prepared by reacting the amine of the Formula



VIII

with a diketone of the general Formula

5




(wherein L is a leaving group). However, the preparation of the diketone of the Formula IX is neither described in the prior art citation nor is it exemplified and therefore this process is but of theoretical importance.

According to a further known process a compound of the general Formula




(wherein L₁ is a leaving group) is reacted with a piperidine derivative of the general Formula

6




(wherein L is a leaving group). The prior art lacks an enabling disclosure and for this reason the skilled art worker is not in the position to carry out said process.

ES-P 2,050,069 aims to overcome the disadvantages of the known procedures. According to said Spanish patent a reactive derivative of the general Formula III is reacted with the ketone of the Formula




whereupon the piperidone derivative of the Formula

7



formed is reacted with hydroxylamine and finally the oxime of the Formula



thus obtained is subjected to cyclization in an inert solvent in the presence of a base. Cyclization which leads to risperidone is carried out either in water in the presence of an alkali hydroxide, alkali carbonate or alkali hydrogencarbonate, or is performed in tetrahydrofuran or dioxan in the presence of an alkali hydride or alkali alkoxide. Ring-closure is preferably carried out in aqueous medium, advantageously at the boiling point of the reaction mixture.


The advantage of this process is that the formation of the dimer of the Formula VII is eliminated. However, this process is accompanied by a very serious draw-back because the piperidone derivative of the Formula XIII formed in the synthesis can be purified only in a very complicated manner either by means of chromatography or *via* the poorly crystallizable hydrochloride. This has the consequence that the piperidone derivative is obtained only in relatively low yields. According to ES-P 2,050,069 the yield is only 63.1 %. Moreover, we failed to reproduce the process with such yields because according to our experiments the yield of the hydrochloride of the piperidone derivative of the Formula XIII is below 60 %. According to ES-P 2,050,069 the conversion of the piperidone derivative of the Formula XIII into the corresponding oxime of the Formula II is carried out with a yield of 76.2 %. We have succeeded in reproducing the process according to ES-P 2,050,069 only with a yield of about 63 %. According to ES-P 2,050,069 the yield of the cyclization of the oxime of the Formula II to risperidone is 79-85 %, but we could reproduce only a yield of about 75 %. Thus the process disclosed in the Spanish patent is not economical either. The aforesaid is illustrated by comparative Example 3.

SUMMARY OF THE INVENTION

It is the object of the present invention to elaborate an economical process for the preparation of risperidone.

The above object is solved by the present invention.

According to the present invention there is provided a process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula I and pharmaceutically acceptable acid addition salts thereof by subjecting the oxime of the Formula II to ring-closure in the presence of an alkali hydroxide, alkali carbonate or alkali-C₁₋₄-alkoxide in a C₁₋₄-alcohol as an inert organic solvent, converting the base of the Formula I thus obtained into an acid addition salt or setting free the base of the Formula I from an acid addition salt thereof which comprises reacting a halogen derivative of the general Formula



XIV

(wherein Hal is halogen) with the piperidine oxime derivative of the Formula V or an acid addition salt thereof in the presence of a base, and using by the ring-closure of the oxime of the Formula II formed a C₁₋₄-alkanol as inert solvent.

It has been found that risperidone can be economically prepared with high yields in pure form by subjecting the oxime of the Formula II to cyclization in the presence of an alkali hydroxide, alkali carbonate or alkali-C₁₋₄-alkoxide in an inert organic solvent, converting the base of the Formula I thus formed into an acid addition salt or setting free the base of the Formula I from an acid addition salt thereof, whereby a halogen derivative of the general Formula XIV (wherein Hal is halogen) is reacted with the piperidone oxime derivative of the Formula V or an acid addition salt thereof in the presence of a base and by the ring-closure of the oxime of the Formula II thus formed a C₁₋₄-alkanol is used as inert solvent.

By the preparation of the oxime of the Formula II as base an inorganic base (e.g. sodium hydrogencarbonate or potassium carbonate) or an organic base (e.g. triethylamine or pyridine) can be used.

According to the process of the present invention after the reaction of the halogen derivative of the general Formula XIV

and the piperidine oxime derivative of the Formula V or an acid addition salt thereof the oxime of the Formula II precipitates in crystalline form and can be converted in the presence of a C₁₋₄-alkanol into risperidone of the Formula I with a yield of about 95 %.

The process of the present invention is surprising for the person skilled in the art because it could not be foreseen that the piperidine oxime derivative of the Formula V containing two acidic hydrogen atoms or a salt thereof would be alkylated in the presence of a base selectively only on the nitrogen atom. This is so much the more surprising as the oxime of the Formula II can be isolated with a yield exceeding 80 %.

It is furthermore also surprising that while according to ES-P 2,050,069 the ring-closure of the oxime of the Formula II is carried out with a yield of about 75 % only, the process of the present invention enables the carrying out the cyclization with a yield of about 95 %.

The advantage of the process of the present invention is that a pharmaceutically pure product can be prepared in high yields.

Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples.

Example 1

Preparation of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound of the Formula II)

To a solution of 36.0 g (0.16 mole) of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in 800 ml of acetonitrile 44.3 g of 4-(2,4-difluoro-benzoyl)-piperidine-oxime-hydrochloride, 33.6 g of sodium hydrogen carbonate and 0.66 g (4 millimoles) of potassium iodide are added. The reaction mixture is refluxed for 5 hours, cooled to room temperature and the solvent is removed *in vacuo*. The residue is taken up in 700 ml of water and extracted twice with 600 ml of dichloromethane each. The combined organic layers are dried over sodium sulfate and evaporated *in vacuo*. Thus 63.7 g of the title compound are obtained. Yield 92.5 %. M.p.: 180-183 °C.

Example 2

Preparation of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound of the Formula II)

One proceeds as described in Example 1 except that methanol is used in place of acetonitrile. Thus 60.7 g of a product being

identical in all respects with the compound prepared according to Example 1 are obtained. Yield 88.2 %.

Example 3

Preparation of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound of the Formula II)

One proceeds as described in Example 1 except that ethanol is used in place of acetonitrile. Thus 62.1 g of a product being identical in all respects with the compound prepared according to Example 1 are obtained. Yield 90.1 %.

Example 4

Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone of the Formula I)

To a solution of 5.4 g (0.1 mole) of sodium methylate in 60 ml of methanol 8.6 g (0.02 mole) of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one are added with stirring at room temperature. The reaction mixture is refluxed for half an hour, then 100 ml of water are added. The precipitated crystalline product is filtered off, washed with

water and dried. Thus 7.9 g of the title compound are obtained. Yield 96.3 %. According to HPLC analysis the total amount of the impurities is below 0.2 % and the product contains no contamination in an amount above 0.1 % each. The product meets the requirements of Pharmeuropa Vol. 10, No. 2, June 1988 in all respects.

Example 5

Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone of the Formula I)

One proceeds as described in Example 4 except that ethanol is used in place of methanol. Thus 7.7 g of the title compound are obtained. Yield 94.5 %. The product is identical in all respects with the compound prepared according to Example 4.

Example 6

Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone of the Formula I)

One proceeds as described in Example 4 except that 2-propanol is used in place of methanol. Thus 7.5 g of the title compound

are obtained. Yield 91.4 %. The product is identical in all respects with the compound prepared according to Example 4.

Comparative Example 1

Preparation of 4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidine (compound of the Formula IV; reproduction of Example 1 paragraph 4 of HU-P 195,793)

A suspension of 11 g of 4-(2,4-difluoro-benzoyl)piperidine-oxime hydrochloride and 25 g of potassium hydroxide in 25 ml of water is heated to boiling with stirring for 2 hours. The reaction mixture is cooled to room temperature and extracted with toluene. The organic phase is dried over anhydrous sodium sulfate and evaporated *in vacuo*. The residual crude product is recrystallized from petroleum ether. Thus 7.1 g of the title compound are obtained. According to HPLC MS analysis the product contains 5 % of 4-{6-[4'-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-piperidine-1'-yl]-1,2-benzisoxazol-3-yl}-piperidine, as a contamination (compound of the Formula VI).

2.0 g of the above product is subjected to separation by column chromatography (eluent: chloroform - methanol 9 : 1). Thus 57 mg of 4-{6-[4'-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-piperidine-1'-yl]-1,2-benzisoxazol-3-yl}-piperidine are obtained. M.p.: 234-237 °C.

pmr (DMSO- d_6): δ , ppm 1.95(m, 4H, piperidine-CH₂-3',5'), 2.12(m, 4H, piperidine-3,5), 3.10(m, 4H, piperidine-NCH₂-2,6), 3.34(b, xH, piperidine-NCH₂-2',6'+water), 4.03(m, 2H, piperidine-4+piperidine-4'), 7.13(m, 2H, phenyl-4,5), 7.31(m, 1H, phenyl-5'), 7.68-7.80(m, 2H, phenyl-7+phenyl-7'), 8.05(m, 1H, phenyl-4').

Comparative Example 2

A) Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (risperidone of the Formula I; reproduction of Example 1 paragraph 5 of HU-P 195,793)

A mixture of 5.3 g (0.02 mole) of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 4.4 g (0.02 mole) of 4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidine, 8 g (0.075 mole) of sodium carbonate and 0.1 g of potassium iodide in 90 ml of N,N-dimethylformamide is heated at 85-90 °C with stirring overnight. The reaction mixture is cooled, poured into water and the precipitated crystalline product is recrystallized from a mixture of N,N-dimethylformamide and 2-propanol. Thus 3.6 g of the title compound are obtained. Yield 45 %. M.p.: 168-170 °C. According to HPLC-MS analysis the product contains 3 % of 3-{2-[4-{6-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-1'-piperidinyl]-1,2-benzisoxazol-3-

yl}-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one as contaminant compound of the Formula VII.

2.5 g of the above product are subjected to separation by column chromatography (eluent: chloroform - methanol 9 : 1). Thus 10 mg of pure 3-{2-[4-{6-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-1'-piperidinyl]-1,2-benzisoxazol-3-yl}-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one contamination are obtained. M.p.: 208-213 °C.

B) Preparation of 3-{2-[4-{6-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-1'-piperidinyl]-1,2-benzisoxazol-3-yl}-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound of the Formula VII)

A solution of 50 mg (0.12 millimole) of 4-{6-[4'-(6'-fluoro-1',2'-benzisoxazol-3'-yl)-piperidine-1'-yl]-1,2-benzisoxazol-3-yl}-piperidine prepared according to comparative Example 1, 27 mg (0,12 millimole) of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 82 mg (0.6 millimole) of potassium carbonate and a catalytic amount of potassium iodide in acetonitrile is heated to boiling with stirring for 6 hours. The reaction mixture is cooled and the solvent is

evaporated *in vacuo*. To the residue 5 ml of water are added and the mixture is extracted twice with 5 ml of dichloromethane each. The organic phase is dried over anhydrous sodium sulfate and evaporated *in vacuo*. Thus 50 mg of the title compound are obtained. Yield 68 %. M.p.: 209-213 °C. The product is identical in all respects with the product isolated by chromatography according to paragraph A).

pmr (DMSO- d_6): δ , ppm 1.8(m, 6H, tetrahydro-pyrido[1,2-*a*]pyrimidin-7,8,9), 2.10(m, 4H, piperidine-CH₂-3',5'), 2.12(m, 4H, piperidine-3,5), 2.30(s, 3H, CH₃), 2.55(t, 2H, CH₂), 2.83(t, 2H, CH₂), 3.18(m, 4H, piperidine-NCH₂-2,6), 3.30(b, xH, piperidine-NCH₂-2',6'), 4.01(m, 2H, piperidine-4+piperidine-4'), 7.11(m, 2H, phenyl-4,5), 7.30(m, 1H, phenyl-5'), 7.61-7.83(m, 2H, phenyl-7+phenyl-7'), 8.00(m, 1H, phenyl-4').

Comparative Example 3

Reproduction of Examples 8, 9, 10 and 11 of ES-P 2,050,069

A) Preparation of 3-[2-[4-(2,4-difluoro-benzoyl)-piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-*a*]pyrimidin-4-one

A suspension of 29.2 g (0.1116 mole) of 4-(2,4-difluoro-benzoyl)-piperidine-hydrochloride, 25.3 g (0.1117 mole) of 3-

(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 500 ml of acetonitrile, 19.6 g (0.2333 mole) of sodium hydrogencarbonate and 0.25 g (0.0015 mole) of potassium iodide is heated to boiling for 10 hours with stirring. The reaction mixture is cooled to room temperature, to the residue 200 ml of water are added. The mixture is stirred for 30 minutes and extracted with 200 ml of dichloromethane. The organic phase is separated, dried over magnesium sulfate, filtered and the filtrate is evaporated. The oily residue thus obtained is purified as follows:

I) The oily residue is purified on a silica column; eluent: chloroform - methanol 9 : 1. The fractions containing the product are collected and evaporated. The residue is dissolved in 200 ml of dichloromethane, the solution is saturated with gaseous hydrogen chloride. The precipitated crystalline product is filtered and dried. Thus 32.1 g of the title compound are obtained. Yield 58.9 %. According to HPLC chromatography the purity of the product is 96.8 %.

II) The oily residue is dissolved in 200 ml of dichloromethane, the solution is saturated with gaseous hydrogen chloride. Because no crystalline product is precipitated from the solution, the solvent is evaporated.

The residual oily product is triturated with diethyl ether for a longer period of time. Crystallization is initiated by seeding with a crystal of the desired compound. Thus 27.9 g of the title compound are obtained. Yield 51.2 %. According to HPLC analysis the purity of the product is 94.8 %.

B) Preparation of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

To a solution of 7.0 g (0.0143 mole) of 3-[2-[4-(2,4-difluorobenzoyl)-piperidino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 70 ml of pyridine, 5.4 g (0.0777 mole) of hydroxylamine hydrochloride and 100 ml of ethanol 1.6 g (0.0286 mole) of potassium hydroxide are added. The reaction mixture is heated to boiling for 10 hours, cooled to room temperature and the solvent is removed *in vacuo*. To the residue 100 ml of water are added and the mixture is extracted with 100 ml of dichloromethane. The organic phase is washed twice with 50 ml of water each, dried over anhydrous magnesium sulfate and evaporated. The residual crude product is recrystallized from ethyl acetate. Thus 4.2 g of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

are obtained. Yield 65.1 %. According to HPLC analysis the purity of the product is 97.2 %.

C) Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

To a suspension of 40 mg (0.9166 millimole) of 55 % sodium hydride and 2 ml of tetrahydrofuran 0.1089 g (0.2532 millimole) of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one is added. The reaction mixture is heated to boiling for an hour, whereupon 5 ml of water are added and the mixture is extracted twice with 10 ml of dichloromethane each. The combined organic phases are dried over magnesium sulfate and evaporated *in vacuo*. Thus 80 mg of the title compound are obtained, yield 77 %. According to HPLC analysis the purity of the product is 97.5 %.


D) Preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one

A solution of 1 g (0.0023 mole) of 3-[2-[4-[(2,4-difluorophenyl)-(hydroxyimino)-methyl]-1-piperidinyl]ethyl]-


6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and 1 g of potassium hydroxide in 10 ml of water is heated to boiling for an hour. The reaction mixture is cooled to room temperature and extracted twice with 10 ml of dichloromethane each. The organic phase is evaporated. Thus 0.70 g of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one are obtained, yield 73.5 %. According to HPLC analysis the purity of the product is 96.4 %.

What we claim is,

1. Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula




and pharmaceutically acceptable acid addition salts thereof by
subjecting the oxime of the Formula




to ring-closure in the presence of an alkali hydroxide, alkali carbonate or alkali-C₁₋₄-alkoxide in an inert organic solvent, converting the base of the Formula I thus obtained into an acid addition salt or setting free the base of the Formula I from an

25

acid addition salt thereof which comprises reacting a halogen derivative of the general Formula







(wherein Hal is halogen) with piperidine oxime derivative of the Formula




or an acid addition salt thereof in the presence of a base, and using by the ring-closure of the oxime of the Formula II formed a C₁₋₄-alkanol as inert solvent.


2. Process according to Claim 1 which comprises using a halogen derivative of the general Formula XIV wherein Hal stands for chlorine.

3. Process according to Claim 1 which comprises using the hydrochloride salt of the piperidine oxime derivative of the Formula V.
4. Process according to Claim 1 which comprises using sodium hydrogencarbonate as base.
5. Process according to Claim 1 which comprises using methanol as C₁₋₄-alkanol.
6. Process according to Claim 1 which comprises using ethanol as C₁₋₄-alkanol.
7. Process according to Claim 1 which comprises using isopropanol as C₁₋₄-alkanol.







V




VI




VII




VIII




IX




X




XI



XII



XIII



XIV

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 196 132 A (JANSSEN PHARMACEUTICA NV) 1 October 1986 (1986-10-01) cited in the application claim 12 -----	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

6 March 2003

Date of mailing of the international search report

17/03/2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Wolf, C

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0196132	A	01-10-1986	SG 119294 G 17-03-1995
			AU 579232 B2 17-11-1988
			AU 5529786 A 02-10-1986
			BG 60432 B2 31-03-1995
			CA 1256867 A1 04-07-1989
			CN 86101906 A ,B 01-10-1986
			CY 1801 A 17-02-1995
			DK 143986 A 28-09-1986
			EP 0196132 A2 01-10-1986
			HK 108794 A 14-10-1994
			IE 58388 B1 08-09-1993
			JP 1908510 C 24-02-1995
			JP 6013511 B 23-02-1994
			JP 61221186 A 01-10-1986
			LU 88576 A9 21-03-1995
			SU 1468419 A3 23-03-1989
			US 4804663 A 14-02-1989
			AT 79379 T 15-08-1992
			CS 9103822 A3 13-05-1992
			DE 3686341 D1 17-09-1992
			DE 3686341 T2 14-01-1993
			ES 8705881 A1 01-08-1987
			FI 861328 A ,B, 28-09-1986
			FI 893001 A 19-06-1989
			GR 860800 A1 21-07-1986
			HU 42461 A2 28-07-1987
			IL 78250 A 12-05-1991
			KR 9100165 B1 21-01-1991
			KR 9100437 B1 25-01-1991
			LT 2071 R3 15-06-1993
			LV 5043 A3 10-06-1993
			LV 5778 A4 20-12-1996
			NO 861230 A ,B, 29-09-1986
			NZ 215462 A 29-09-1988
			PH 24016 A 09-02-1990
			PT 82254 A ,B 01-04-1986
			SK 280125 B6 06-08-1999
			ZA 8602279 A 25-11-1987

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.